Monash IVF Overview
- Year Founded
-
1971
- Status
-
Public
- Employees
-
508
- Stock Symbol
-
MVF
- Investments
-
5
- Share Price
-
$0.87
- (As of Friday Closing)
Monash IVF General Information
Description
Monash IVF Group Ltd is a specialist assisted reproductive services provider. The company offers specialist diagnostic obstetric and gynaecological ultrasound and fertility treatments. The company's operating segment includes Australia and International. It generates maximum revenue from the Australian segment. Australian segment is a provider of Assisted Reproductive Services, Ultrasound, and other related services. The International segment is a provider of Assisted Reproductive Services in Malaysia.
Contact Information
- Pelaco Building Level 1
- 21-31 Goodwood Street
- Richmond, Victoria
- Australia
Monash IVF Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.87 | $0.86 | $0.62 - $0.88 | $341M | 390M | 773K | $0.04 |
Monash IVF Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2023 | FY 2023 30-Jun-2023 | FY 2022 30-Jun-2022 | FY 2021 30-Jun-2021 |
|---|---|---|---|---|
| EV | 357,469 | 357,469 | 301,021 | 278,500 |
| Revenue | 143,592 | 143,592 | 139,349 | 136,884 |
| EBITDA | 32,579 | 32,579 | 31,274 | 38,233 |
| Net Income | 14,682 | 14,682 | 13,338 | 18,749 |
| Total Assets | 279,265 | 279,265 | 261,968 | 263,846 |
| Total Debt | 66,219 | 66,219 | 53,127 | 34,553 |
Monash IVF Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Monash IVF Comparisons
Industry
Financing
Details
000000
Monash IVF Competitors (1)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| 000000 000000 | Private Equity-Backed | Greenwich, Australia | 0000 | 00000 | 000000000000 | 00000 |
Monash IVF Patents
Monash IVF Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2019902204-A0 | Methods of predicting endometrial receptivity | Inactive | 25-Jun-2019 | ||
| EP-3990663-A1 | Methods of predicting endometrial receptivity | Pending | 25-Jun-2019 | 0000000000 | |
| US-20220268780-A1 | Methods of predicting endometrial receptivity | Pending | 25-Jun-2019 | 0000000000 | |
| AU-2020302958-A1 | Methods of predicting endometrial receptivity | Pending | 25-Jun-2019 | 0000000000 | |
| CA-3145010-A1 | Methods of predicting endometrial receptivity | Pending | 25-Jun-2019 | G01N33/689 |
Monash IVF Executive Team (13)
Monash IVF Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 000000000 | Monash IVF | Board Member | 000 0000 |
| 0000000 00000 | Monash IVF | Independent Chairman | 000 0000 |
| 0000000 0000000 | Self | Executive Director | 000 0000 |
Monash IVF Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Monash IVF Acquisitions (5)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| PIVET Medical Centre | 31-Mar-2023 | 0000000000 | 00.000 | Clinics/Outpatient Services | 0000000 0 |
| ART Associates Queensland #2 | 30-Sep-2022 | 0000000000 | 00.000 | Other Healthcare Services | 0000000 0 |
| Fertility Solutions | 10-Jul-2019 | 0000000000 | 00.000 | Clinics/Outpatient Services | 0000000 0 |
| Sydney Ultrasound for Women | 17-Jun-2015 | 0000000000 | 000.00 | Clinics/Outpatient Services | 00000 000 |
| Fertility Australia | 05-Dec-2014 | Merger/Acquisition | 00.000 | Clinics/Outpatient Services |
Monash IVF Subsidiaries (3)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Fertility Solutions | Clinics/Outpatient Services | Buderim, Australia | 2007 |
| Sydney Ultrasound for Women | Clinics/Outpatient Services | Bella Vista, Australia | 0000 |
| PIVET Medical Centre | Clinics/Outpatient Services | Leederville, Australia | 0000 |
Monash IVF ESG
Risk Overview
Risk Rating
Updated March, 23, 2021
29.45 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,189
Rank
Percentile
Pharmaceuticals
Industry
00 of 901
Rank
Percentile
Biotechnology
Subindustry
00 of 403
Rank
Percentile
